25
|
Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst 2014; 106:dju149. [PMID: 24957074 DOI: 10.1093/jnci/dju149] [Citation(s) in RCA: 98] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND ATP-binding cassette (ABC) transporters play various roles in cancer biology and drug resistance, but their association with outcomes in serous epithelial ovarian cancer (EOC) is unknown. METHODS The relationship between clinical outcomes and ABC transporter gene expression in two independent cohorts of high-grade serous EOC tumors was assessed with real-time quantitative polymerase chain reaction, analysis of expression microarray data, and immunohistochemistry. Associations between clinical outcomes and ABCA transporter gene single nucleotide polymorphisms were tested in a genome-wide association study. Impact of short interfering RNA-mediated gene suppression was determined by colony forming and migration assays. Association with survival was assessed with Kaplan-Meier analysis and log-rank tests. All statistical tests were two-sided. RESULTS Associations with outcome were observed with ABC transporters of the "A" subfamily, but not with multidrug transporters. High-level expression of ABCA1, ABCA6, ABCA8, and ABCA9 in primary tumors was statistically significantly associated with reduced survival in serous ovarian cancer patients. Low levels of ABCA5 and the C-allele of rs536009 were associated with shorter overall survival (hazard ratio for death = 1.50; 95% confidence interval [CI] =1.26 to 1.79; P = 6.5e-6). The combined expression pattern of ABCA1, ABCA5, and either ABCA8 or ABCA9 was associated with particularly poor outcome (mean overall survival in group with adverse ABCA1, ABCA5 and ABCA9 gene expression = 33.2 months, 95% CI = 26.4 to 40.1; vs 55.3 months in the group with favorable ABCA gene expression, 95% CI = 49.8 to 60.8; P = .001), independently of tumor stage or surgical debulking status. Suppression of cholesterol transporter ABCA1 inhibited ovarian cancer cell growth and migration in vitro, and statin treatment reduced ovarian cancer cell migration. CONCLUSIONS Expression of ABCA transporters was associated with poor outcome in serous ovarian cancer, implicating lipid trafficking as a potentially important process in EOC.
Collapse
Affiliation(s)
- Ellen L Hedditch
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Bo Gao
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Amanda J Russell
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Yi Lu
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Catherine Emmanuel
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Jonathan Beesley
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Sharon E Johnatty
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Xiaoqing Chen
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Paul Harnett
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Joshy George
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | | | - Rebekka T Williams
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Claudia Flemming
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Diether Lambrechts
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Evelyn Despierre
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Sandrina Lambrechts
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Ignace Vergote
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Beth Karlan
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Jenny Lester
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Sandra Orsulic
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Christine Walsh
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Peter Fasching
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Matthias W Beckmann
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Arif B Ekici
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Alexander Hein
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Keitaro Matsuo
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Satoyo Hosono
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Toru Nakanishi
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Yasushi Yatabe
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Tanja Pejovic
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Yukie Bean
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Florian Heitz
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Philipp Harter
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Andreas du Bois
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Ira Schwaab
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Estrid Hogdall
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Susan K Kjaer
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Allan Jensen
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Claus Hogdall
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Lene Lundvall
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Svend Aage Engelholm
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Bob Brown
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - James Flanagan
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Michelle D Metcalf
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Nadeem Siddiqui
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Thomas Sellers
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Brooke Fridley
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Julie Cunningham
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Joellen Schildkraut
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Ed Iversen
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Rachel P Weber
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Andrew Berchuck
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Ellen Goode
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - David D Bowtell
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Georgia Chenevix-Trench
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Anna deFazio
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Murray D Norris
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Stuart MacGregor
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Michelle Haber
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| | - Michelle J Henderson
- Affiliations of authors: Children's Cancer Institute Australia, Randwick, Australia (ELH, AJR, RTW, CF, MDN, MH, MJH); Department of Gynaecological Oncology and Westmead Institute for Cancer Research (BG, CE, AOCSG, AdF), Crown Princess Mary Cancer Centre and Westmead Institute for Cancer Research (PH) University of Sydney at the Westmead Millennium Institute, Westmead Hospital, Sydney, Australia; Queensland Institute of Medical Research, Brisbane, Australia (YL, JB, SEJ, XC, AOCSG, GC-T, SM); Peter MacCallum Cancer Centre, Melbourne, Australia (JG, AOCSG, DDB); Vesalius Research Center, VIB, Leuven, Belgium (DL); Department of Oncology, University of Leuven and University Hospitals Leuven, Leuven, Belgium (ED, SL, IV); Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA (BK, JL, SO, CW); Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Germany (PF, MWB, AH); University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA (PF); Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan (ABE, KM, SH); Department of Gynecology (TN), and Department of Pathology and Molecular Diagnostics (YY), Aichi Cancer Center Central Hospital, Nagoya, Aichi, Japan; Department of Obstetrics and Gynecology (TP, YB), and Knight Cancer Institute (TP, YB), Oregon Health & Science University, Portland, OR; Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Erlangen, Germany (FH); Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany (FH); De
| |
Collapse
|